-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LiNAE8soIGiODV9a8pS7Q/oaTOio3uV5H5nAa1LGCX+oz+eeoPfJAHi9+lfj/7SA EXrRGsxmCV0KhN6hrXJqOg== 0000864009-98-000003.txt : 19980525 0000864009-98-000003.hdr.sgml : 19980525 ACCESSION NUMBER: 0000864009-98-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19980522 ITEM INFORMATION: FILED AS OF DATE: 19980522 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: INNOVIR LABORATORIES INC CENTRAL INDEX KEY: 0000901099 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133536290 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-21972 FILM NUMBER: 98630452 BUSINESS ADDRESS: STREET 1: 510 E 73RD ST CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2122494703 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 1998 INNOVIR LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 0-21972 13-3536290 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 510 East 73rd Street, New York, NY 10021 - ---------------------------------- ------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (212) 249-4703 Not Applicable (Former name or former address, if changed since last report) Item 5. Other Events. On May 19, 1998 Innovir Laboratories, Inc. issued the press release filed herewith as Exhibit 99. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (a) Financial Statements No financial statements are required to be filed as a part of this report. (b) Pro Forma Financial Information No pro forma financial information is required to be filed as a part of this report. (c) Exhibits 99 Press release, dated May 19, 1998. All other Items of this report are inapplicable. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INNOVIR LABORATORIES, INC. Date: May 22, 1998 By:/s/ FRANCIS M. O'CONNELL ------------------------ Name: Francis M. O'Connell Title: Chief Financial Officer EXHIBIT INDEX 99 Press release, dated May 19, 1998. EX-99 2 PRESS RELEASE EXHIBIT 99 For Immediate Release Media Contact: Laura A. Mastrangelo VIMRX Pharmaceuticals 302-998-1734/Pager 800-916-8038 Investor Contact: Dian Griesel, Ph.D. The Investor Relations Group 212-664-8489 INNOVIR TO REFOCUS OLIGOZYME DEVELOPMENT PROGRAM Company Further Reduces Overall Operating Expenses NEW YORK, NY, MAY 19, 1998 - Innovir Laboratories, Inc. (Nasdaq SmallCap: INVR), a subsidiary of VIMRX Pharmaceuticals Inc. (Nasdaq: VMRX), today announced a strategic refocusing of its oligozyme development program in an effort to increase scientific productivity in those areas with the most commercial potential, while reducing overall operational expenses in order to better conserve its limited capital resources. Innovir will focus efforts on the recently discovered FRS (Functional Ribozyme Selection) and related technologies which depend on the lead EGS (External Guide Sequence) technology licensed from Yale University and further developed by Innovir scientists. Innovir plans to restructure the research and development of its ribozyme-based technology, now being developed primarily in its European operations in Goettingen, Germany, and Cambridge, England. Innovir will seek partners or investors in the ribozyme-based technology. If new investors are not found, management intends to close the two sites and consolidate research into the New York operations. Through this strategic refocusing, Innovir estimates that it will be able to further reduce its annualized expenses by approximately 50%, resulting in an approximately 70% reduction from its 1997 spend rate by 4Q, 1998, while still enabling progress to occur in the further development and commercial exploitation of the FRS and related technologies. "In spite of the demonstrated promise of the ribozyme-based technology, Innovir's limited resources make it impossible for our scientific team to do an adequate job of developing both it and the EGS-based FRS technology," said Dr. Thomas R. Sharpe, president and CEO of Innovir. "The business opportunities presented by the FRS technology, which gives us the ability to solve one of the important problems impeding progress in the oligonucleotide field - how to quickly identify the optimum cleavage site in an RNA molecule -- require us to focus our resources on that opportunity." Innovir Laboratories, Inc. Innovir Laboratories, Inc. is a biotechnology company that is developing technologies based on catalytically interactive oligomers (oligozymes) for pharmaceutical and genomic research. As a research tool, oligozymes can help determine the functions of genes and validate molecular targets for new drug therapies. The Company's technologies will utilize External Guide Sequences (EGS) oligozymes - which inactivate targeted messenger RNA (mRNA). To complement its drug target validation programs, Innovir has developed FRS (Functional Ribozyme Selection) for identifying the optimal cleavage sites in bacterial cells. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company's periodic reports on Form 10-K and 10-Q, and any prospectus describing the Company's securities. # # # NOTE TO INVESTORS AND EDITORS: Innovir's press releases are available on the Internet through www.vimrx.com and through BusinessWire's web site at http://www.businesswire.com. The releases also are available at no charge through BusinessWire's fax-on-demand service at 800-411-8792. -----END PRIVACY-ENHANCED MESSAGE-----